Silo Pharma wins US patent allowance for SPC — 15 PTSD treatment claims

Silo Pharma received a USPTO notice of allowance for a U.S. patent covering SPC-15, an intranasal candidate for PTSD. Allowed claims cover compositions, methods to prevent or mitigate stress-induced behavioral responses. Decision extends IP protection for SPC-15, the company’s lead program. Japan previously issued a corresponding patent for the same invention earlier this year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via (Ref. ID: 202609180850PRIMZONEFULLFEED9829526) on September 18, 2026, and is solely responsible for the information contained therein. (C)